# Denali Therapeutics Inc.

Denali Therapeutics Inc. is a public company listed on Nasdaq as DNLI, headquartered in South San Francisco, CA, United States.

## Company overview

- **Legal name:** Denali Therapeutics Inc.
- **Classification:** Public company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** South San Francisco, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **Ticker:** Nasdaq: DNLI
- **SEC CIK:** 0001714899

## About

Denali Therapeutics Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001714899, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2026-02-26, it reported annual revenue of USD 0; net income of USD -512,540,000; total assets of USD 1,144,854,000 for the fiscal period ended 2025-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Revenue:** $0 (USD 0)
- **Net income:** -$512.5M (USD -512,540,000)
- **Total assets:** $1.1B (USD 1,144,854,000)
- **Cash and equivalents:** $205.3M (USD 205,326,000)
- **Operating cash flow:** -$412.6M (USD -412,600,000)

### FY2024 (period ended 2024-12-31)

- **Revenue:** $0 (USD 0)
- **Net income:** -$422.8M (USD -422,773,000)
- **Total assets:** $1.4B (USD 1,374,180,000)
- **Cash and equivalents:** $175.0M (USD 174,960,000)
- **Operating cash flow:** -$347.7M (USD -347,694,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $330.5M (USD 330,531,000)
- **Net income:** -$145.2M (USD -145,224,000)
- **Total assets:** $1.2B (USD 1,153,917,000)
- **Cash and equivalents:** $127.1M (USD 127,106,000)
- **Operating cash flow:** -$358.0M (USD -357,991,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $108.5M (USD 108,463,000)
- **Net income:** -$326.0M (USD -325,991,000)
- **Total assets:** $1.5B (USD 1,460,242,000)
- **Cash and equivalents:** $218.0M (USD 218,044,000)
- **Operating cash flow:** -$244.7M (USD -244,716,000)

## Recent SEC filings

- Form 10-Q — filed 2026-08-06 — period 2026-06-30 — 10-Q
- Form 8-K — filed 2026-08-06 — period 2026-08-06 — 8-K
- Form 8-K — filed 2026-07-28 — period 2026-07-27 — 8-K
- Form 8-K — filed 2026-06-18 — period 2026-06-12 — 8-K
- Form 8-K — filed 2026-06-04 — period 2026-06-03 — 8-K
- Form 8-K — filed 2026-05-22 — period 2026-05-21 — 8-K
- Form 10-Q — filed 2026-05-07 — period 2026-03-31 — 10-Q
- Form 8-K — filed 2026-05-07 — period 2026-05-07 — 8-K
- Form DEF 14A — filed 2026-04-21 — period 2025-12-31 — DEF 14A
- Form 8-K — filed 2026-04-03 — period 2026-04-03 — 8-K
- Form 8-K — filed 2026-03-31 — period 2026-03-27 — 8-K
- Form 8-K — filed 2026-03-25 — period 2026-03-25 — 8-K

---

Updated: 2026-10-23T05:02:54.863002+00:00

Canonical page: https://altss.com/profile/denali-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology